Advertisement

Topics

Clinical Trials About "Testing Immune Hotspots Predict Risk That Breast Cancer" RSS

13:50 EDT 26th May 2018 | BioPortfolio

We list hundreds of Clinical Trials about "Testing Immune Hotspots Predict Risk That Breast Cancer" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Testing Immune Hotspots Predict Risk That Breast Cancer" on BioPortfolio

We have published hundreds of Testing Immune Hotspots Predict Risk That Breast Cancer news stories on BioPortfolio along with dozens of Testing Immune Hotspots Predict Risk That Breast Cancer Clinical Trials and PubMed Articles about Testing Immune Hotspots Predict Risk That Breast Cancer for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Testing Immune Hotspots Predict Risk That Breast Cancer Companies in our database. You can also find out about relevant Testing Immune Hotspots Predict Risk That Breast Cancer Drugs and Medications on this site too.

Showing "Testing Immune Hotspots Predict Risk That Breast Cancer" Clinical Trials 1–25 of 38,000+

Extremely Relevant

Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women

RATIONALE: Studying mammograms for breast density changes over time may help doctors predict breast cancer risk. PURPOSE: This natural history study is looking at changes in breast density and gathering health information over time to assess breast cancer risk in women with breast cancer and in healthy women.


Relevant

Predict the Risk of Axillary Metastases in Breast Cancer Patients With Axillary Ultrasound

Axillary lymph node status is a vital prognostic factors in breast cancer patients and provides crucial information for making treatment decisions.This projective observational study is planned to identify risk factors for axillary metastases in breast cancer patients with axillary ultrasound and to construct a nomogram to predict the risk of axillary metastases in these patients.

A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)

This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc. is testing a form of immune therapy (vaccine) to see if it can be used to make the immune system attack the cancer. The study includes administration of additional treatments, in combination, thought to enhance the immune response effect. (CDX 1307-01)


Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer

RATIONALE: Analyzing genes for changes before and after chemotherapy may help doctors predict a patient's response to treatment and help plan the most effective treatment. PURPOSE: This clinical trial is studying how well genetic testing works in predicting response to paclitaxel in women who have unresected breast cancer.

Engineering Gut Microbiome to Target Breast Cancer

The purpose of this study is to find out if using probiotics will help the body's immune system react to breast cancer. New studies showed that diverse species of bacteria inside the bowel might help improve immune system, particularly the ability of immune system to recognize cancer. This study will investigate how probiotics will affect the subjects' immune system on breast cancer.

Effects of Rapid Genetic Counseling and Testing in Newly Diagnosed Breast Cancer Patients

5-10% of breast cancer patients carry a mutation in the BRCA1 or BRCA2 gene. Genetic counseling and DNA testing are usually offered to selected patients after primary treatment has been completed (e.g. the first year after diagnosis). For women with a mutation in one of the two breast-ovarian cancer syndrome genes, chances of a second breast cancer are high, and therefore a proportion of these women may opt for preventive measures in addition to their immediate breast cancer tr...

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

The purpose of this study is to learn more about how to treat patients with HER-2/neu positive invasive breast cancer (IBC). HER-2/neu is a type of protein that is known to be over-expressed in aggressive breast cancer. The study drug for this trial is DC1 study vaccine which is a HER2-sensitized dendritic cell (DC) study vaccine. This study vaccine is made from the participant's blood cells collected from a procedure called leukapheresis. Dendritic cells are immune cells that...

Comparison of Genes in Healthy Women, Women at High Risk for Breast Cancer, and Women With Breast Cancer

RATIONALE: Genetic testing for specific genes that are associated with estrogen may help identify patients who are at greatest risk for developing breast cancer. PURPOSE: This clinical trial is studying genetic differences in healthy women, women at high risk for breast cancer, and women who have breast cancer.

A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer

This is a multicentre, single-arm prospective cohort study evaluating risk of ipsilateral breast tumour recurrence(IBTR) following breast conserving surgery (BCS) in a group of women postulated to be at low risk for recurrence. Women with luminal A breast cancer determined by immunohistochemical(IHC) and other low risk clinical testing (see below) will be treated with endocrine therapy (tamoxifen or aromatase inhibitor) for five years and will not be treated with breast irradia...

Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer

This study is being done to see if it is possible to use blood samples to predict response to treatment in breast cancer patients receiving preoperative (or neoadjuvant) therapy. Research has shown that most breast cancers release tumor-specific DNA into the blood (that is, DNA that is specific to the tumor cells or cancer). This DNA can be detected in blood testing known as plasma tumor-DNA or "ptDNA." This DNA is separate from that found in your blood and tissue samples which...

Breast Imaging and Time of Menstrual Cycle in Women With a Genetic Risk of Breast Cancer

RATIONALE: Screening tests may help doctors detect cancer cells early and plan more effective treatment for breast and ovarian cancer. PURPOSE: Study to determine how screening at different times in the menstrual cycle may affect the results of imaging procedures in women who have a genetic risk of breast or ovarian cancer.

Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)

Objectives: - To evaluate the attitudes and opinions of women undergoing genetic counseling for hereditary breast and ovarian cancer syndrome, both before and after testing, in regards to pregnancy and fertility Hypothesis: -Factors that will increase the percentage of women endorsing prenatal diagnostic testing will include a personal history of breast or ovarian cancer, having had a mother or sister die of breast or ovarian cancer, and testing positive for a B...

Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer

This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc. is testing a form of immune therapy (vaccine) to see if it can be used to make the immune system attack the cancer. The study includes administration of additional treatments, in combination, thought to enhance the immune response effect. This study specifically administers the vaccine systemically to explore whether dendritic cell targeted v...

Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure

This is an open-label, multicentric, international, phase II trial testing aromatase inhibitors in combination with durvalumab in patients with CD8+ T cell infiltration (>10% CD8+ T cells in the tumor). The trial includes two sequences: The first part of the treatment will consist in 4-6 weeks treatment with immune-attractants; in the second part, CD8+ patients will receive 6 months of durvalumab combined with exemestane.

Decision Support for BRCA Testing in Ethnically Diverse Women

The objective of this study is to expand genetic testing for hereditary breast and ovarian cancer syndrome to a broader population of high-risk women by prompting appropriate referrals from the primary care setting with the use of an electronic health record-embedded breast cancer risk navigation (BNAV) tool. To address patient-related barriers to genetic testing, we developed a web-based decision aid, RealRisks, which is designed to improve genetic testing knowledge, accuracy ...

Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence

RATIONALE: Vaccines may make the body build an immune response and decrease the recurrence of breast cancer. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who are at high risk for breast cancer recurrence.

Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake

The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS), in addition to the standard National Cancer Institute's Breast Cancer Risk Assessment Tool (BCRAT) or Tyrer-Cuzick (IBIS) score, will aid women at risk of breast cancer in making a decision to take (or not take) medications to prevent breast cancer

Nutrition-Related Biomarkers in Predicting Breast Cancer Risk in Women

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about nutrition-related changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict a woman's risk of developing breast cancer. PURPOSE: This laboratory study is looking at nutrition-related biomarkers in predicting breast cancer risk in women.

Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer

RATIONALE: Exercise may change the risk of developing breast cancer. It is not yet known whether low-intensity exercise or high-intensity exercise is more effective in lowering the risk of breast cancer. PURPOSE: This randomized clinical trial is studying how well exercise programs work in healthy young women at increased risk of developing breast cancer.

Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study

The overall goal of the proposed research is to evaluate the uptake of testing and longitudinal risks and benefits of multiplex testing for cancer susceptibility in BRCA1/2 negative patients. This model will inform the selection of the outcomes and potential mediators and moderators of these outcomes, to inform the debate over utility, risks, and benefits of clinical incorporation of multiplex testing for breast cancer susceptibility.

Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70

Description: The trial is designed to determine the response of the immune system of patients with breast cancer to a vaccine made from their own tumor. Researchers believe that this particular vaccine, which is made from purified heat shock proteins taken from each patient's tumor, might alert the body's immune system to recognize and attack invading cancer. To be considered potentially eligible for this study you must be a high risk breast cancer patient and have a tumor that...

Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment

Participating in genetic cancer risk assessments (GCRA) for hereditary breast and ovarian cancer can inform treatment and risk management decisions and improve breast cancer outcomes. However, Latina and Black women underuse GCRA services, which may increase breast cancer disparities. This study will adapt and test the impact of an easily scalable novel Intelligent Tutoring System intervention to enhance GCRA use and improve psychosocial outcomes in a clinical sample of underse...

A Study on the Epidemiology and Testing of Human Epidermal Growth Factor-Receptor 2 (HER2) in Breast Cancer in Germany

This non-interventional study will collect data from routine diagnostics on HER2 testing of breast cancer in Germany.

Combined Breast Cancer Risk Study

A prospective, non-interventional study in women 18 to 84 years of age. Subjects will provide a sample for genetic testing and information about their medical and family history. The results of the genetic test will be combined with clinical data to validate a method of predicting breast cancer risk.

High Risk Breast Cancer Screening Program

Objectives: - To screen population with high risk for breast cancer - To promote the concept and importance of surveillance mammography - To find out the incidence of breast cancer in population who are in high risk for breast cancer - To collect blood samples for molecular analysis


More From BioPortfolio on "Testing Immune Hotspots Predict Risk That Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement